• Kiniksa Pharmaceuticals International PLC KNSA.OQ KNSA.O is expected to show a rise in quarterly revenue when it reports results on July 29 for the period ending June 30 2025

• The London United Kingdom-based company is expected to report a 40.5% increase in revenue to $145.218 million from $103.39 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Kiniksa Pharmaceuticals International PLC is for earnings of 18 cents per share.

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International PLC is $40.00, about 32.8% above its last closing price of $26.90

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated July 25 at 12:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)